July 7th 2025
Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
A Breast Cancer Risk Assessment Tool That Includes Breast Density Measures
Distinct Molecular Tumor Profile in Younger CRC Patients Recognized
Dr Ira Klein Discusses the Use of Fee-for-Service in Oncology
Dissecting the Patient Perception of FDA's Breakthrough Designation
Clinton Seeks Cap on Drug Expenses, Would Let Medicare Negotiate